Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
Answer:
Wild forest fires cause extensive damage to flora and fauna and result in the destruction of man-made property in and around the area of the fire. To maintain the health of the forest and prevent the large wild forest people or man]nagers use prescribe fire or controlled fired when there is no risk of loss of life and resources.
These controlled fires are used by forest officials and fire managers to prevent or keep wildfires at bay. It helps in cleared-off areas by playing the role of a barrier for fire from spreading further.
There is always the risk of flora fauna and the life of wild animals. They can get killed and lose their habitat and the smoke rose from this fire causes for environmental concern too.
Hydrochloric acid is found in the stomach
